Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb7195

Trial Profile

Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb7195

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs XmAb 7195 (Primary) ; XmAb 7195 (Primary)
  • Indications Allergic asthma; Hypersensitivity
  • Focus Pharmacokinetics
  • Sponsors Xencor
  • Most Recent Events

    • 09 May 2017 According to a Xencor media release, top-line data is expected in 2017.
    • 01 May 2017 Status changed from active, no longer recruiting to completed.
    • 23 Mar 2017 Planned End Date changed from 1 Oct 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top